Roche rolls out two new Accu-Chek products
INDIANAPOLIS Roche on Thursday announced the availability of two new tools that can help patients pinpoint food and lifestyle choices that have the biggest impact on their blood glucose levels.
Roche is rolling out the Accu-Chek Testing in Pairs and Accu-Chek 360-degree View tools as a way to help adults, children and teens manage their diabetes more easily and more effectively. The initiative is part of Roche’s Behavior Change through Patient Engagement program.
“Diabetes is a 24/7 disease that doesn’t give patients a day off,” stated Dan Kane, VP marketing for Roche Diabetes Care North America. “It’s relentless, and we understand how difficult it can be to stay motivated, especially when it’s not clear what affects blood sugar levels or why the numbers on a patient’s meter rise and fall like they do. These simple tools bring clarity to the meaning of those numbers and, more importantly, help patients better understand what influences their results — and what they can do to improve them.”
The Accu-Chek Testing in Pairs tool is a paper-based way to track blood sugar responses to everyday situations like stress, exercise and eating out. By comparing before-and-after readings around single events for seven days, patients can zero in on one thing that makes a difference for them, Roche noted.
The Accu-Chek 360-degree View tool is a paper chart that offers a seven-point profile of blood glucose control. In three days, it gives a more complete picture of the effectiveness of prescriptions, as well as how food portions affect blood glucose and energy levels. Discovering these patterns may help patients and their healthcare providers quickly see if adjustments are needed.
“By tracking results over time, patients see how balanced meals and medication — even changes brought about by these simple tools — alter blood sugar levels,” Kane said.“The initiative not only helps people understand their numbers better, it allows them to take a greater role in developing effective plans with their healthcare providers for more successful outcomes.”
J&J: Agreements with Schering-Plough void after Merck merger
NEW BRUNSWICK, N.J. The planned merger between Schering-Plough Corp. and Merck & Co. would permit the termination of agreements between Schering-Plough and Johnson & Johnson’s biotech division, J&J asserted in an arbitration demand filed Wednesday with the American Arbitration Association, an alternative dispute resolution organization.
The drug maker said the planned merger constituted a change of control that would allow the termination between agreements its Centocor Ortho Biotech division made with Schering-Plough regarding the inflammatory and immunological disease drugs Remicade (infliximab) and Simponi (golimumab).
“As its public statements have made clear, Merck is acquiring Schering-Plough,” J&J said in a statement. “The acquisition constitutes a change of control that tribbers the right of our Centocor Ortho Biotech subsidiary to terminate the agreements.”
FDA accepts approval application from Warner Chilcott
ARDEE, Ireland The Food and Drug Administration has accepted an approval application for a low-dose oral contraceptive from Warner Chilcott, the drug maker announced Wednesday.
The agency accepted Warner Chilcott’s new drug application for WC 3016, submitted through a subsidiary on March 26.
The company recently relocated its headquarters from Bermuda to Ireland.